Evidence map›Paper›PMID 40710253›Full record

ArticleBiomimetics (Basel, Switzerland)2025

Fast and Fractionated: Correlation of Dose Attenuation and the Response of Human Cancer Cells in a New Anthropomorphic Brain Phantom.

Bernd Frerker, Elette Engels, Jason Paino, Vincent de Rover, John Paul Bustillo, Marie Wegner, Matthew Cameron, Stefan Fiedler, Daniel Häusermann, Guido Hildebrandt and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomimetics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Bernd FrerkerDepartment of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany.ORCID 0009-0009-1436-6592
Elette EngelsAustralian Synchrotron/ANSTO, Clayton, Melbourne, VIC 3168, Australia.ORCID 0000-0003-4704-2104
Jason PainoCentre of Medical Radiation Physics, University of Wollongong, Wollongong, NSW 2522, Australia.ORCID 0000-0002-3648-7880
Vincent de RoverCentre of Medical Radiation Physics, University of Wollongong, Wollongong, NSW 2522, Australia.
John Paul BustilloCentre of Medical Radiation Physics, University of Wollongong, Wollongong, NSW 2522, Australia.ORCID 0000-0001-8052-0011
Marie WegnerInstitute of Product Development and Mechanical Engineering Design, Hamburg University of Technology, 21073 Hamburg, Germany.ORCID 0000-0001-8616-859X
Matthew CameronAustralian Synchrotron/ANSTO, Clayton, Melbourne, VIC 3168, Australia.ORCID 0000-0002-2792-1892
Stefan FiedlerEuropean Molecular Biology Laboratory (EMBL), Hamburg Outstation, 22607 Hamburg, Germany.ORCID 0000-0002-3623-3311
Daniel HäusermannAustralian Synchrotron/ANSTO, Clayton, Melbourne, VIC 3168, Australia.ORCID 0009-0006-2878-307X
Guido HildebrandtDepartment of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany.ORCID 0000-0002-0498-2692
Michael LerchCentre of Medical Radiation Physics, University of Wollongong, Wollongong, NSW 2522, Australia.ORCID 0000-0002-2406-9972
Elisabeth SchültkeDepartment of Radiooncology, Rostock University Medical Center, 18059 Rostock, Germany.ORCID 0000-0002-1273-0065

Funding

Australian Government noneAustralian Institute of Nuclear Science noneAustralian Synchrotron noneDeutsche Forschungsgemeinschaft SCHU 2589/7-3German Academic Exchange Service 57650979German Academic Exchange Service 57751378
6 · The paper itself

Abstract

The results of radiotherapy in patients with primary malignant brain tumors are extremely dissatisfactory: the overall survival after a diagnosis of glioblastoma is typically less than three years. The development of spatially fractionated radiotherapy techniques could help to improve this bleak prognosis. In order to develop technical equipment and organ-specific therapy plans, dosimetry studies as well as radiobiology studies are conducted. Although perfect spheres are considered optimal phantoms by physicists, this does not reflect the wide variety of head sizes and shapes in our patient community. Depth from surface and X-ray dose absorption by tissue between dose entry point and target, two key parameters in medical physics planning, are largely determined by the shape and thickness of the skull bone. We have, therefore, designed and produced a biomimetic tool to correlate measured technical dose and biological response in human cancer cells: a brain phantom, produced from tissue-equivalent materials. In a first pilot study, utilizing our phantom to correlate technical dose measurements and metabolic response to radiation in human cancer cell lines, we demonstrate why an anthropomorphic phantom is preferable over a simple spheroid phantom.

Indexed as

anthropomorphic phantombiomimetic toolbrainhuman cancer cell linesmicrobeam radiation therapy (MRT)spatial dose fractionation (SFRT)synchrotron

Identifiers

PMID40710253
PMCPMC12292920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.